TORONTO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQB:BSXGF) announces that the Federal Court of Altamira, Pará, Brazil, denied the Company’s request for recognition of provisional compliance with a prior judgment of the Federal Court of Appeals. That appellate judgment conditioned the effectiveness of the Construction…
Gardena, California, March 11, 2026 (GLOBE NEWSWIRE) -- OLDPGS – Old Patrolman Guard Services, a California-based security services company, has announced that it is currently in discussions with authorities in Belize, Central America, to obtain the required licenses to establish and operate a security services firm in the country.
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC, March 11, 2026 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSXV:FOBI) (Pink: FOBIF) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, advises that its previously announced non-brokered private placement financing…
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Lilypath today officially launched, defining Authority Intelligence™ as a new category for the AI era, one built to help professionals understand, shape and protect how artificial intelligence systems interpret their credibility, expertise and professional authority.
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved…
